{
  "extraction_metadata": {
    "timestamp": "2025-09-05T13:15:09.837534",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 3,
    "total_picos": 19
  },
  "picos_by_country": {
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "overall survival (OS; median, hazard ratio, Kaplan-Meier estimates at 12 months), progression-free survival (PFS; median, hazard ratio, Kaplan-Meier estimates, subgroup analyses), objective response rate (ORR; primary endpoint, RECIST v1.1), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event rate (assessed by CTCAE v5.0), rate of grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life, including change from baseline to week 12 and time to deterioration of overall health status and physical functioning), serious adverse events, deaths, withdrawal of consent, loss to follow-up"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel + nintedanib",
          "Outcomes": "overall survival (OS; median, hazard ratio, Kaplan-Meier estimates at 12 months), progression-free survival (PFS; median, hazard ratio, Kaplan-Meier estimates, subgroup analyses), objective response rate (ORR; primary endpoint, RECIST v1.1), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event rate (assessed by CTCAE v5.0), rate of grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life, including change from baseline to week 12 and time to deterioration of overall health status and physical functioning), serious adverse events, deaths, withdrawal of consent, loss to follow-up"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "overall survival (OS; median, hazard ratio, Kaplan-Meier estimates at 12 months), progression-free survival (PFS; median, hazard ratio, Kaplan-Meier estimates, subgroup analyses), objective response rate (ORR; primary endpoint, RECIST v1.1), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event rate (assessed by CTCAE v5.0), rate of grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life, including change from baseline to week 12 and time to deterioration of overall health status and physical functioning), serious adverse events, deaths, withdrawal of consent, loss to follow-up"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "overall survival (OS; median, hazard ratio, Kaplan-Meier estimates at 12 months), progression-free survival (PFS; median, hazard ratio, Kaplan-Meier estimates, subgroup analyses), objective response rate (ORR; primary endpoint, RECIST v1.1), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event rate (assessed by CTCAE v5.0), rate of grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life, including change from baseline to week 12 and time to deterioration of overall health status and physical functioning), serious adverse events, deaths, withdrawal of consent, loss to follow-up"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "overall survival (OS; median, hazard ratio, Kaplan-Meier estimates at 12 months), progression-free survival (PFS; median, hazard ratio, Kaplan-Meier estimates, subgroup analyses), objective response rate (ORR; primary endpoint, RECIST v1.1), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event rate (assessed by CTCAE v5.0), rate of grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life, including change from baseline to week 12 and time to deterioration of overall health status and physical functioning), serious adverse events, deaths, withdrawal of consent, loss to follow-up"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "overall survival (OS; median, hazard ratio, Kaplan-Meier estimates at 12 months), progression-free survival (PFS; median, hazard ratio, Kaplan-Meier estimates, subgroup analyses), objective response rate (ORR; primary endpoint, RECIST v1.1), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event rate (assessed by CTCAE v5.0), rate of grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life, including change from baseline to week 12 and time to deterioration of overall health status and physical functioning), serious adverse events, deaths, withdrawal of consent, loss to follow-up"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "platinum doublet",
          "Outcomes": "overall survival (OS; median, hazard ratio, Kaplan-Meier estimates at 12 months), progression-free survival (PFS; median, hazard ratio, Kaplan-Meier estimates, subgroup analyses), objective response rate (ORR; primary endpoint, RECIST v1.1), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event rate (assessed by CTCAE v5.0), rate of grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life, including change from baseline to week 12 and time to deterioration of overall health status and physical functioning), serious adverse events, deaths, withdrawal of consent, loss to follow-up"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy and tumours expressing PD-L1 with a TPS >=1%",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "overall survival (OS; median, hazard ratio, Kaplan-Meier estimates at 12 months), progression-free survival (PFS; median, hazard ratio, Kaplan-Meier estimates, subgroup analyses), objective response rate (ORR; primary endpoint, RECIST v1.1), duration of response (DoR), disease control rate, time to progression, time to next treatment, event-free survival, duration of treatment, adverse event rate (assessed by CTCAE v5.0), rate of grade 3-4 adverse events, discontinuation rate due to adverse events, mortality-related toxicity, quality of life (overall health status/quality of life, including change from baseline to week 12 and time to deterioration of overall health status and physical functioning), serious adverse events, deaths, withdrawal of consent, loss to follow-up"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10908
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 negative tumours and adenocarcinoma histology",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy and PD-L1 expressing tumours (PD-L1 expression ≥ 1% of tumour cells)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded, independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology and health status (assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (EQ-5D VAS), health-related quality of life (data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, interstitial lung disease (severe AE), liver disorders (severe AEs), stomatitis (AE), peripheral oedema (AE), peripheral neuropathy (AE), alopecia (AE), blood and lymphatic system disorders (AE), fatigue (AE), fever (AE), infections and infestations (AE)"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10591
    },
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "",
          "Outcomes": "progression-free survival (PFS; median values reported: 5.6 months [95% CI: 4.3, 7.8] in CodeBreaK 200, 6.7 months [95% CI: 4.6, 8.3] in Awad 2022, 6.1 months [95% CI: 5.6, not reached] in Julve 2021, 6.3 months [95% CI: 5.3, 8.2] in CodeBreaK 100), overall survival (OS; median 12.5 months [95% CI: 10.0, not achieved] in CodeBreaK 100), overall response rate (ORR; 28% for sotorasib vs 13% for docetaxel in CodeBreaK 200), disease control rate (DCR; 83% for sotorasib vs docetaxel), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires; includes assessment of general health, functioning, and lung cancer symptoms such as pain, swelling, difficulty breathing, loss of hair, bleeding in the chest, and cough), serious adverse events (SAEs; RR [95% CI]=0.47 [0.28, 0.80] for sotorasib vs docetaxel), adverse events of grade ≥3 (23% of patients in Awad 2022; RR [95% CI]=1.19 [1.01, 1.40] for sotorasib vs docetaxel), treatment-related adverse events (65% of patients in Awad 2022), treatment-related adverse events leading to discontinuation (7% of patients in Awad 2022; RR [95% CI]=2.33 [1.52, 3.57] for sotorasib vs docetaxel), dose modification-related adverse drug reactions (26% of patients in Awad 2022), treatment-associated adverse events resulting in death (1% of patients in Awad 2022), frequency of specific adverse events (≥10% of patients; diarrhoea, increased ALT, increased AST, constipation, anaemia, fatigue, fever, peripheral oedema, shortness of breath, cough, vomiting, decreased appetite, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia), incremental cost-utility ratio (ICUR) from the public payer perspective, quality of life in Polish clinical practice (proposed for real-world data collection)"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10268
    }
  }
}